Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $40.84 Billion |
|---|---|
| Enterprise Value | $36.96 Billion |
| Earnings per Share | $33.8 |
| Beta | 0.52 |
| Outstanding Shares | 111,575,811 |
| P/E Ratio | 27.82 |
|---|---|
| PEG | 18.39 |
| Price to Sales | 6.78 |
| Price to Book Ratio | 7.96 |
| Enterprise Value to Revenue | 6.03 |
| Enterprise Value to EBIT | 38 |
| Enterprise Value to Net Income | 56 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.24 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 72.81% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.15%▼ 31.19% |
|---|---|
| Total Invested | $58.62M▼ 99.41% |
| Investors Holding | 40▼ 256.00% |
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer ...
Stockcircle shows 44 open-market insider sales for BeOne Medicines AG in the last six months from SEC Form 4 reports by executives, directors, and other insiders.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.